Perindopril |
Catalog No.GC16871
One-Click Copy Product Info
|
Perindopril is an angiotensin-converting enzyme (ACE) inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 82834-16-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Perindopril is an angiotensin-converting enzyme (ACE) inhibitor. Perindopril lowers blood pressure and cardiac load by inhibiting the conversion of angiotensin I to angiotensin II and reducing the degradation of bradykinin. Perindopril is used in the treatment of hypertension and heart failure[1-4].
In vitro, differentiated SH-SY5Y cells were pretreated with Perindopril (1-10μg/mL) for 24 hours, followed by stimulation with LPS (20μg/mL) for 1 hour. Perindopril significantly increased cell viability but showed no significant effects on acetylcholine (ACh) levels or the expression of pro-inflammatory factors (TNF-α, IL-1β, NFκB)[5]. Perindopril (100μM) treated THP-1 macrophages for 24 hours. Perindopril inhibited SARS-CoV-2 Spike protein (100nM)-induced apoptosis, reactive oxygen species generation, and MHC-II expression[6].
In vivo, Swiss mice were orally administered Perindopril (1mg/kg; single dose) 1 hour before establishing chemical, thermal, and mechanical pain models. Perindopril significantly reduced the number of writhes in mice, delayed reaction times in the tail clip test, and increased latency in the hot plate test[7]. Starting 1 hour before a single intraperitoneal injection of cisplatin (10mg/kg), Swiss mice were orally administered Perindopril (2mg/kg; once daily) for 5 consecutive days. Perindopril significantly improved cisplatin-induced renal histological changes, levels of inflammatory factors (TNF-α, IL-6, IL-10), and expression of apoptosis-related proteins (Bax, Bcl2, caspase-3)[8].
References:
[1] Alfakih K, Hall AS. Perindopril. Expert Opin Pharmacother. 2006 Jan;7(1):63-71.
[2] Lababidi JM, Kabil MF, Azzazy HME. Perindopril: A comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2026;51:211-252.
[3] Ghiadoni L. Perindopril for the treatment of hypertension. Expert Opin Pharmacother. 2011 Jul;12(10):1633-42.
[4] Simpson D, Noble S, Goa KL. Perindopril: in congestive heart failure. Drugs. 2002;62(9):1367-77.
[5] Şen S, Hacıosmanoğlu E. Comparing the Neuroprotective Effects of Telmisartan, Perindopril, and Nebivolol Against Lipopolysaccharide-Induced Injury in Neuron-Like Cells. Cureus. 2022 Jul 29;14(7):e27429.
[6] Barhoumi T, Alghanem B, Shaibah H, et al. SARS-CoV-2 Coronavirus Spike Protein-Induced Apoptosis, Inflammatory, and Oxidative Stress Responses in THP-1-Like-Macrophages: Potential Role of Angiotensin-Converting Enzyme Inhibitor (Perindopril). Front Immunol. 2021 Sep 20;12:728896.
[7] Suresha RN, Amoghimath S, Vaibhavi PS, et al. Evaluation of analgesic activity of perindopril in albino mice. J Adv Pharm Technol Res. 2014 Jul;5(3):129-33.
[8] Aljuhani N, Ismail RS, El-Awady MS, et al. Modulatory effects of perindopril on cisplatin-induced nephrotoxicity in mice: Implication of inflammatory cytokines and caspase-3 mediated apoptosis. Acta Pharm. 2020 Dec 1;70(4):515-525.
| Cell experiment [1]: | |
Cell lines | Differentiated SH-SY5Y cell line (human neuroblastoma cell line differentiated to neuronal phenotype) |
Preparation Method | Cells were differentiated with retinoic acid for one week in serum-free neurobasal medium. Cells were pre-treated with LPS (20μg/mL) for one hour, then exposed to Perindopril at concentrations of 1-10μg/mL for 24 hours. |
Reaction Conditions | 1-10μg/mL; 24 hours |
Applications | Perindopril significantly increased cell viability against LPS-induced injury at all doses. Perindopril showed no statistically significant changes in acetylcholine (ACh) levels after LPS-induced injury. No significant changes in TNF-α, IL-1β, and NFκB expressions were detected with the administration of Perindopril. |
| Animal experiment [2]: | |
Animal models | Swiss albino mice (Swiss strain) |
Preparation Method | The mcie received Perindopril (1mg/kg) per orally. Perindopril were administered 2h before the experiment. Analgesic activity was evaluated using Eddy's hot plate (thermal pain), acetic acid-induced writhing (chemical pain), and tail clip (mechanical pain) methods. |
Dosage form | 1mg/kg; orally; single dose administered 2h before testing |
Applications | Perindopril significantly decreased the number of writhes in the acetic acid-induced writhing test, delayed the reaction time in the tail clip method, and increased the latency period in the Eddy's hot plate method compared to the control group, demonstrating analgesic activity in thermal, chemical, and mechanical pain models. |
References: | |
| Cas No. | 82834-16-0 | SDF | |
| Chemical Name | (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid | ||
| Canonical SMILES | CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O | ||
| Formula | C19H32N2O5 | M.Wt | 368.47 |
| Solubility | Ethanol: 25 mg/ml,PBS (pH 7.2): 10 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7139 mL | 13.5696 mL | 27.1393 mL |
| 5 mM | 542.8 μL | 2.7139 mL | 5.4279 mL |
| 10 mM | 271.4 μL | 1.357 mL | 2.7139 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)